Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
Vistagen (Nasdaq: VTGN) announced new findings at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., supporting the mechanism of action of fasedienol (PH94B), a nasal spray in Phase 3 development for social anxiety disorder (SAD). The study revealed that fasedienol is metabolized locally in the nasal passages, not requiring systemic uptake, thereby enhancing its safety profile. Over 30,000 doses have been administered without adverse effects. This first-in-class therapy acts on nasal receptors to activate amygdala circuits, presenting a novel treatment approach compared to traditional therapies which often have delayed onset and significant side effects. These developments position Vistagen favorably within the biopharmaceutical landscape, focusing on innovative solutions for anxiety and depression.
Vistagen (NASDAQ: VTGN) announced the European Patent Office granted a patent for AV-101, an oral NMDAR glycine site antagonist aimed at treating CNS disorders. This patent supports the synthesis of AV-101 in commercial quantities and mirrors a U.S. patent effective until at least 2039. The company views AV-101 as a potential treatment for conditions like Parkinson's dyskinesia, major depressive disorder, and neuropathic pain. CEO Shawn Singh emphasized the importance of expanding the patent portfolio for future development and commercialization strategies. AV-101 shows promising preclinical results and is well-tolerated in clinical studies, leading to its Fast Track designation by the FDA for major depressive disorder and neuropathic pain. Vistagen aims to revolutionize treatment for anxiety and depression while avoiding significant side effects associated with current therapies.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
